Degussa Goldschmidt Personal Care and Helix BioMedix announce Partnership on Peptides

Goldschmidt GmbH, a wholly owned subsidiary of Degussa GmbH and
leading global manufacturer of raw materials, additives and active
ingredients for the cosmetic industry, and Helix BioMedix, Inc.,
(OTCBB: HXBM), a biopharmaceutical company with an extensive library
of diverse bioactive peptides, today announced an agreement through
which Degussa Goldschmidt Personal Care will become Helix BioMedix's
exclusive marketing partner for its Combikine(TM) and Replikine(TM)
class of anti-aging peptides in addition to other selected peptides
targeted at skin care applications.

"We are extremely pleased about our agreement with Helix BioMedix
since it will allow us to complement our existing product portfolio of
specialty and active ingredients for the cosmetic industry," remarks
Willy Klipp, Senior Vice President and General Manager of Goldschmidt,
Personal Care. "This cooperation is a further important move in
growing our customer relationships and guaranteeing the consistent
implementation of our overall strategy. We are currently evaluating
several peptides and plan that initial products developed as a result
of this partnership will be commercially available as of 2008."

"Partnering with a company of Degussa's stature will assist us as
we continue to commercialize our innovative peptides," commented R.
Stephen Beatty, President and Chief Executive Officer of Helix
BioMedix. "Degussa Goldschmidt Personal Care is one of the leading
manufacturers of cosmetic ingredients worldwide, with an impressive
portfolio and an excellent reputation for product development and
service. We look forward to continuing our work with them, and
anticipate that over the term of this agreement our joint efforts will
produce many innovative personal care products covering a variety of
applications and benefits."

"Bioactive peptides are emerging as some of today's most promising
answers to the constant demand for innovation in bio-science,"
explains Dr. Mike Farwick, Head of R&D Active Ingredients for
Goldschmidt, Personal Care. "Accessing Helix BioMedix's portfolio of
innovative peptides and combining it with our extensive formulation
know-how and claims validation capabilities substantially supports our
competitive advantage in creating the next generation of safe and
effective personal care products."

About Goldschmidt GmbH

Goldschmidt GmbH's business line Personal Care is a leading global
manufacturer and supplier of raw materials, additives, and active
ingredients for the cosmetics industry. All business activities are
strongly supported by application technology, as well as by own
in-house research & development. A dedicated team of highly skilled
professionals is committed to excellence and customer satisfaction.
Among other products Goldschmidt is specialised in manufacturing human
skin identical sphingolipids including Ceramides by biotech means.
Screening, identification and confirmation of biological activities
for novel ingredients is carried with state-of-the-art cell and
molecular biology including the use of DNA-Chip technology, cell
cultures, artificial skin models and the validation of results in
in-vivo studies.

About Helix BioMedix, Inc.

Helix BioMedix, Inc. is a biopharmaceutical company with an
extensive library of diverse bioactive peptides and patents covering
six distinct classes and hundreds of thousands of peptide sequences.
The company's mission is to enrich clinical practice and the
patient/consumer experience by developing topically applied products
that offer the health, beauty and safety benefits of advanced
bioactive small molecule technology. The Company's vision is to be
recognized as the world leader in the identification, qualification
and commercialization of natural and synthetic peptide technology.

The core competencies of Helix BioMedix include peptide design,
synthesis and characterization together with assay development,
screening, tissue culture and microbiology, leveraged through
relationships with contract research organizations and peptide
manufacturers. The company has the capability to take product
development programs from theoretical concept to a validated and
qualified skin care active ingredient fully validated as to efficacy
and safety. Applications for Helix BioMedix peptides include
anti-aging cosmeceutical skin care and acne treatment as well as other
topical anti-infective pharmaceuticals and wound healing applications.
In addition, the company is developing finished, peptide-based
products to market with its partners.

More information about Helix BioMedix and its proprietary peptides
may be found on the company's website at www.helixbiomedix.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding
Helix BioMedix, Inc. (statements which are not historical facts)
within the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements include statements regarding
activities, events or developments that Helix BioMedix, Inc. expects,
believes or anticipates may occur in the future, including statements
related to its potential growth, product development and
commercialization and revenue. A number of factors could cause actual
results to differ from those indicated in the forward-looking
statements, including the company's ability to successfully raise
additional capital, enter into revenue generating license agreements,
continue its research and development efforts, including pre-clinical
and clinical studies, continue developing marketable peptide-based
products and general economic conditions. Additional assumptions,
risks and uncertainties are described in detail in the company's
reports and other filings with the Securities and Exchange Commission.
Such filings are available on the Helix BioMedix, Inc. website or at
www.sec.gov. Readers are cautioned that such forward-looking
statements are not guarantees of future performance and that actual
results or developments may differ materially from those set forth in
the forward-looking statements. Helix BioMedix, Inc. undertakes no
obligation to publicly update or revise forward-looking statements to
reflect subsequent events or circumstances.